These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23481630)

  • 1. CD99 and HLA-II immunostaining in breast cancer tissue and their correlation with lymph node metastasis.
    Baccar A; Ferchichi I; Troudi W; Marrakchi R; Ben Hmida N; Jebini S; Mrad K; Ben Romdhane K; Benammar Elgaaied A
    Dis Markers; 2013; 34(5):363-71. PubMed ID: 23481630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD99 correlates with low cyclin D1, high topoisomerase 2 status and triple negative molecular phenotype but is prognostically irrelevant in breast carcinoma.
    Czapiewski P; Wełnicka-Jaśkiewicz M; Seroczyńska B; Skokowski J; Sejda A; Szade J; Wiewiora C; Biernat W; Żaczek A
    Pol J Pathol; 2015 Sep; 66(3):269-75. PubMed ID: 26619106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody.
    O'Neill AF; Dearling JL; Wang Y; Tupper T; Sun Y; Aster JC; Calicchio ML; Perez-Atayde AR; Packard AB; Kung AL
    Clin Cancer Res; 2014 Feb; 20(3):678-87. PubMed ID: 24218512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased immunoreactivity of CD99 is an independent predictor of regional lymph node metastases in pulmonary carcinoid tumors.
    Pelosi G; Leon ME; Veronesi G; Spaggiari L; Pasini F; Viale G
    J Thorac Oncol; 2006 Jun; 1(5):468-77. PubMed ID: 17409901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of immunohistochemistry for CD99 in the identification of matrix-producing carcinoma of the breast.
    Walker JA; Carder PJ
    Histopathology; 2003 Mar; 42(3):300-1. PubMed ID: 12605650
    [No Abstract]   [Full Text] [Related]  

  • 6. CD99/MIC-2 surface protein expression in breast carcinomas.
    Milanezi F; Pereira EM; Ferreira FV; Leitão D; Schmitt FC
    Histopathology; 2001 Dec; 39(6):578-83. PubMed ID: 11903575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical study of CD99 and EMA expression in ependymomas.
    Mahfouz S; Aziz AA; Gabal SM; el-Sheikh S
    Medscape J Med; 2008 Feb; 10(2):41. PubMed ID: 18382710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors.
    Ishizawa K; Komori T; Shimada S; Hirose T
    Clin Neuropathol; 2008; 27(3):118-28. PubMed ID: 18552083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical fibroxanthoma presenting immunoreactivity against CD10 and CD99.
    Nakamura Y; Abe Y; Ichimiya M; Muto M
    J Dermatol; 2010 Apr; 37(4):387-9. PubMed ID: 20507414
    [No Abstract]   [Full Text] [Related]  

  • 10. CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours.
    Pelosi G; Fraggetta F; Sonzogni A; Fazio N; Cavallon A; Viale G
    Virchows Arch; 2000 Sep; 437(3):270-4. PubMed ID: 11037347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of CD99 protein expression in pancreatic endocrine tumours (PETs).
    Goto A; Niki T; Terado Y; Fukushima J; Fukayama M
    Histopathology; 2004 Oct; 45(4):384-92. PubMed ID: 15469477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of tumor-associated macrophages in breast carcinoma invasion and metastasis.
    Yang J; Li X; Liu X; Liu Y
    Int J Clin Exp Pathol; 2015; 8(6):6656-64. PubMed ID: 26261547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways.
    Byun HJ; Hong IK; Kim E; Jin YJ; Jeoung DI; Hahn JH; Kim YM; Park SH; Lee H
    J Biol Chem; 2006 Nov; 281(46):34833-47. PubMed ID: 16984917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoexpression of inhibin alpha subunit, inhibin/activin betaA subunit and CD99 in ovarian tumors.
    Choi YL; Kim HS; Ahn G
    Arch Pathol Lab Med; 2000 Apr; 124(4):563-9. PubMed ID: 10747314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the potential of immunohistochemistry for systematic gene expression profiling.
    Warford A; Flack G; Conquer JS; Zola H; McCafferty J
    J Immunol Methods; 2007 Jan; 318(1-2):125-37. PubMed ID: 17141799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD99 immunoreactivity in ependymoma.
    Choi YL; Chi JG; Suh YL
    Appl Immunohistochem Mol Morphol; 2001 Jun; 9(2):125-9. PubMed ID: 11396629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A metastatic melanoma with an unusual immunophenotypic profile.
    Gao Z; Stanek A; Chen S
    Am J Dermatopathol; 2007 Apr; 29(2):169-71. PubMed ID: 17414440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD99 immunoreactivity in atypical fibroxanthoma and pleomorphic malignant fibrous histiocytoma: a useful diagnostic marker.
    Hartel PH; Jackson J; Ducatman BS; Zhang P
    J Cutan Pathol; 2006 Sep; 33 Suppl 2():24-8. PubMed ID: 16972949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD99 expression in dermatofibrosarcoma protuberans and dermatofibroma.
    Kazlouskaya V; Malhotra S; Kabigting FD; Lal K; Elston DM
    Am J Dermatopathol; 2014 May; 36(5):392-6. PubMed ID: 24247571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High CD99 expression in memory T and B cells in reactive lymph nodes.
    Park CK; Shin YK; Kim TJ; Park SH; Ahn GH
    J Korean Med Sci; 1999 Dec; 14(6):600-6. PubMed ID: 10642936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.